Does alpha-lipoic acid ameliorate cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy?
Alpha-lipoic acid demonstrates therapeutic potential for diabetic cardiomyopathy by ameliorating cardiac fibrosis and dysfunction in an experimental model.
These results, coupled with the excellent safety and tolerability profile of ALA in humans, demonstrate that ALA may have therapeutic potential in the treatment of DCM by attenuating MOS, ECM remodeling and JNK, p38 MAPK activation.
Li et al. (Tue,) studied this question.